Efficacy | PBO | 1 mg QD | 2 mg QD | 4 mg QD | 8 mg QD |
---|---|---|---|---|---|
(N=49) | (N=24) | (N=24) | (N=24) | (N=24) | |
% ACR20* | 31 | 67‡ | 83‡ | 67‡ | 88‡ |
% ACR50* | 8 | 33‡ | 46‡ | 50‡ | 54‡ |
% DAS28-CRP <2.6† | 22 | 29 | 33 | 38 | 38 |
% DAS28-CRP <3.2† | 31 | 50 | 63‡ | 67‡ | 79‡ |
% SDAI ≤3.3† | 8 | 4 | 29‡ | 17 | 17 |
% HAQ-DI ≤0.5† | 45 | 50 | 54 | 63 | 83‡ |
% Pts achieving improvement from baseline of ≥0.22 (MCID) | 29 | 54‡ | 58‡ | 75‡ | 71‡ |